

# Stephen J Fowler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4561508/publications.pdf>

Version: 2024-02-01

153  
papers

6,498  
citations

66234

42  
h-index

76769

74  
g-index

154  
all docs

154  
docs citations

154  
times ranked

7296  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. <i>European Respiratory Journal</i> , 2015, 46, 1308-1321.	3.1	434
2	A European Respiratory Society technical standard: exhaled biomarkers in lung disease. <i>European Respiratory Journal</i> , 2017, 49, 1600965.	3.1	432
3	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1797-1807.	1.5	236
4	Application of <sup>TM</sup> omics technologies to biomarker discovery in inflammatory lung diseases. <i>European Respiratory Journal</i> , 2013, 42, 802-825.	3.1	234
5	Dysfunctional breathing: a review of the literature and proposal for classification. <i>European Respiratory Review</i> , 2016, 25, 287-294.	3.0	217
6	The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. <i>European Respiratory Journal</i> , 2015, 46, 1322-1333.	3.1	179
7	Exhaled breath analysis: a review of <sup>TM</sup> breath-taking <sup>TM</sup> methods for off-line analysis. <i>Metabolomics</i> , 2017, 13, 110.	1.4	178
8	Non-invasive phenotyping using exhaled volatile organic compounds in asthma. <i>Thorax</i> , 2011, 66, 804-809.	2.7	173
9	A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 443-455.	2.5	165
10	Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics. <i>European Respiratory Journal</i> , 2006, 28, 1204-1210.	3.1	145
11	Taking your breath away: metabolomics breathes life in to personalized medicine. <i>Trends in Biotechnology</i> , 2014, 32, 538-548.	4.9	132
12	Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. <i>Thorax</i> , 2017, 72, 129-136.	2.7	130
13	Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. <i>Analyst, The</i> , 2010, 135, 315.	1.7	119
14	Electronic cigarette exposure triggers neutrophil inflammatory responses. <i>Respiratory Research</i> , 2016, 17, 56.	1.4	117
15	Pathway discovery using transcriptomic profiles in adult-onset severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1280-1290.	1.5	105
16	Exhaled Volatile Organic Compounds of Infection: A Systematic Review. <i>ACS Infectious Diseases</i> , 2017, 3, 695-710.	1.8	96
17	High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 822-824.e2.	1.5	89
18	Breathomics in the setting of asthma and chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 970-976.	1.5	88

#	ARTICLE	IF	CITATIONS
19	Composite type-2 biomarker strategy versus a symptom-based risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 57-68.	5.2	88
20	BreathDx – molecular analysis of exhaled breath as a diagnostic test for ventilator-associated pneumonia: protocol for a European multicentre observational study. <i>BMC Pulmonary Medicine</i> , 2017, 17, 1.	0.8	84
21	Screening for Bronchial Hyperresponsiveness Using Methacholine and Adenosine Monophosphate. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1318-1322.	2.5	82
22	Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. <i>Respiratory Research</i> , 2012, 13, 72.	1.4	80
23	IL-17 – high asthma with features of a psoriasis immunophenotype. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1198-1213.	1.5	80
24	Laryngeal Dysfunction: Assessment and Management for the Clinician. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1062-1072.	2.5	78
25	Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1811-1820.e7.	1.5	74
26	Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 771-779.e10.	1.5	72
27	The VCDQ – a Questionnaire for symptom monitoring in vocal cord dysfunction. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1406-1411.	1.4	69
28	Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. <i>Annals of Allergy, Asthma and Immunology</i> , 2003, 90, 194-198.	0.5	62
29	Perspectives of patients and healthcare professionals on mHealth for asthma self-management. <i>European Respiratory Journal</i> , 2017, 49, 1601966.	3.1	61
30	Stratification of asthma phenotypes by airway proteomic signatures. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 70-82.	1.5	59
31	Interventions for bronchiectasis: an overview of Cochrane systematic reviews. <i>The Cochrane Library</i> , 2015, 2015, CD010337.	1.5	56
32	Detecting laryngopharyngeal reflux in patients with upper airways symptoms: Symptoms, signs or salivary pepsin?. <i>Respiratory Medicine</i> , 2015, 109, 963-969.	1.3	56
33	The potential role of exhaled breath analysis in the diagnostic process of pneumonia – a systematic review. <i>Journal of Breath Research</i> , 2018, 12, 024001.	1.5	56
34	Surveillance for lower airway pathogens in mechanically ventilated patients by metabolomic analysis of exhaled breath: a case-control study. <i>Thorax</i> , 2015, 70, 320-325.	2.7	54
35	Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. <i>Clinical and Experimental Allergy</i> , 2003, 33, 783-788.	1.4	53
36	Time of Day Affects Eosinophil Biomarkers in Asthma: Implications for Diagnosis and Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1578-1581.	2.5	53

#	ARTICLE	IF	CITATIONS
37	MyAirCoach: the use of home-monitoring and mHealth systems to predict deterioration in asthma control and the occurrence of asthma exacerbations; study protocol of an observational study. <i>BMJ Open</i> , 2017, 7, e013935.	0.8	51
38	Objective Cough Frequency, Airway Inflammation, and Disease Control in Asthma. <i>Chest</i> , 2016, 149, 1460-1466.	0.4	49
39	Urinary Leukotriene E <sub>4</sub> and Prostaglandin D <sub>2</sub> Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 37-53.	2.5	49
40	Exhaled breath testing – A tool for the clinician and researcher. <i>Paediatric Respiratory Reviews</i> , 2019, 29, 37-41.	1.2	48
41	Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a beclomethasone alone. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 929-935.	1.5	46
42	Breath metabolomic profiling by nuclear magnetic resonance spectroscopy in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1050-1056.	2.7	46
43	Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1602298.	3.1	44
44	Burden of fungal asthma in Africa: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0216568.	1.1	43
45	Diminished airway macrophage expression of the Axl receptor tyrosine kinase is associated with defective efferocytosis in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1144-1146.e4.	1.5	42
46	Effectiveness of myAirCoach: A mHealth Self-Management System in Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1972-1979.e8.	2.0	42
47	A benchmarking protocol for breath analysis: the peppermint experiment. <i>Journal of Breath Research</i> , 2020, 14, 046008.	1.5	41
48	Effects of Adding Either a Leukotriene Receptor Antagonist or Low-Dose Theophylline to a Low or Medium Dose of Inhaled Corticosteroid in Patients With Persistent Asthma. <i>Chest</i> , 2002, 122, 151-159.	0.4	40
49	Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 731-734.	2.5	40
50	<i>Pseudomonas aeruginosa</i> -Derived Volatile Sulfur Compounds Promote Distal <i>Aspergillus fumigatus</i> Growth and a Synergistic Pathogen-Pathogen Interaction That Increases Pathogenicity in Co-infection. <i>Frontiers in Microbiology</i> , 2019, 10, 2311.	1.5	39
51	Circadian rhythm of exhaled biomarkers in health and asthma. <i>European Respiratory Journal</i> , 2019, 54, 1901068.	3.1	37
52	Allergen challenge increases capsaicin-evoked cough responses in patients with allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 788-795.e1.	1.5	37
53	Treatable traits in the European Uâ€œscp>BIOPRED</scp> adult asthma cohorts. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 406-411.	2.7	37
54	5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 187-190.	0.8	35

#	ARTICLE	IF	CITATIONS
55	Fungal sensitisation in severe asthma is associated with the identification of <i>Aspergillus fumigatus</i> in sputum. <i>Journal of Asthma</i> , 2016, 53, 732-735.	0.9	34
56	Headspace volatile organic compounds from bacteria implicated in ventilator-associated pneumonia analysed by TD-GC/MS. <i>Journal of Breath Research</i> , 2018, 12, 026002.	1.5	33
57	Inhaled hyperosmolar agents for bronchiectasis. <i>The Cochrane Library</i> , 2014, 2014, CD002996.	1.5	32
58	Contribution of airway eosinophils in airway wall remodeling in asthma: Role of MMP-10 and MET. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1102-1112.	2.7	32
59	Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 823-829.	2.5	31
60	The interaction between bronchoconstriction and cough in asthma. <i>Thorax</i> , 2017, 72, 1144-1146.	2.7	29
61	Volatile organic compound signature from co-culture of lung epithelial cell line with <i>Pseudomonas aeruginosa</i> . <i>Analyst</i> , 2018, 143, 3148-3155.	1.7	28
62	Exhaled volatile organic compounds as markers for medication use in asthma. <i>European Respiratory Journal</i> , 2020, 55, 1900544.	3.1	27
63	A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. <i>Trials</i> , 2018, 19, 5.	0.7	26
64	TD/GC-MS analysis of volatile markers emitted from mono- and co-cultures of <i>Enterobacter cloacae</i> and <i>Pseudomonas aeruginosa</i> in artificial sputum. <i>Metabolomics</i> , 2018, 14, 66.	1.4	26
65	Pharmacokinetics and systemic $\beta_2$ -adrenoceptor-mediated responses to inhaled salbutamol. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 359-362.	1.1	25
66	Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 93-95.	1.1	25
67	Relationship of skin-prick reactivity to aeroallergens and hyperresponsiveness to challenges with methacholine and adenosine monophosphate. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 46-52.	2.7	25
68	Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review. <i>Respiratory Research</i> , 2019, 20, 7.	1.4	25
69	Volatile organic compounds associated with diagnosis and disease characteristics in asthma – A systematic review. <i>Respiratory Medicine</i> , 2020, 169, 105984.	1.3	25
70	Therapeutic Ratio of Hydrofluoroalkane and Chlorofluorocarbon Formulations of Fluticasone Propionate. <i>Chest</i> , 2002, 122, 618-623.	0.4	24
71	Effects of high relative humidity and dry purging on VOCs obtained during breath sampling on common sorbent tubes. <i>Journal of Breath Research</i> , 2020, 14, 046006.	1.5	23
72	Methodology validation, intra-subject reproducibility and stability of exhaled volatile organic compounds. <i>Journal of Breath Research</i> , 2012, 6, 026002.	1.5	22

#	ARTICLE	IF	CITATIONS
73	Development of an adaptable headspace sampling method for metabolic profiling of the fungal volatome. <i>Analyst, The</i> , 2018, 143, 4155-4162.	1.7	22
74	eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1045-1055.	1.5	22
75	Mapping atopic dermatitis and anti-IL-22 response signatures to type 2 low severe neutrophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 89-101.	1.5	22
76	Methodological considerations for large-scale breath analysis studies: lessons from the U-BIOPRED severe asthma project. <i>Journal of Breath Research</i> , 2019, 13, 016001.	1.5	20
77	Clinical presentation, assessment, and management of inducible laryngeal obstruction. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2018, 26, 174-179.	0.8	19
78	Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma. <i>Respiratory Medicine</i> , 2019, 150, 66-73.	1.3	19
79	The peppermint breath test: a benchmarking protocol for breath sampling and analysis using GC-MS. <i>Journal of Breath Research</i> , 2021, 15, 026006.	1.5	19
80	Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort. <i>PLoS ONE</i> , 2018, 13, e0203874.	1.1	18
81	Asthma Diagnosis: The Changing Face of Guidelines. <i>Pulmonary Therapy</i> , 2019, 5, 103-115.	1.1	18
82	Lipid phenotyping of lung epithelial lining fluid in healthy human volunteers. <i>Metabolomics</i> , 2018, 14, 123.	1.4	17
83	Exhaled breath metabolomics reveals a pathogen-specific response in a rat pneumonia model for two human pathogenic bacteria: a proof-of-concept study. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 316, L751-L756.	1.3	17
84	Biomarkers in adult asthma: a systematic review of 8-isoprostane in exhaled breath condensate. <i>Journal of Breath Research</i> , 2017, 11, 016011.	1.5	16
85	Large-Scale Label-Free Quantitative Mapping of the Sputum Proteome. <i>Journal of Proteome Research</i> , 2018, 17, 2072-2091.	1.8	16
86	Assessment of adherence to corticosteroids in asthma by drug monitoring or fractional exhaled nitric oxide: A literature review. <i>Clinical and Experimental Allergy</i> , 2021, 51, 49-62.	1.4	16
87	Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. <i>Thorax</i> , 2002, 57, 865-868.	2.7	15
88	Reduction in peripheral blood eosinophil counts after bronchial thermoplasty. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 308-310.e2.	1.5	15
89	Epithelial dysregulation in obese severe asthmatics with gastro-oesophageal reflux. <i>European Respiratory Journal</i> , 2019, 53, 1900453.	3.1	15
90	Triggers of breathlessness in inducible laryngeal obstruction and asthma. <i>Clinical and Experimental Allergy</i> , 2020, 50, 1230-1237.	1.4	15

#	ARTICLE	IF	CITATIONS
91	Refractory asthma â€œ beyond step 5, the role of new and emerging adjuvant therapies. <i>Chronic Respiratory Disease</i> , 2015, 12, 69-77.	1.0	14
92	Asthma diagnosis: into the fourth dimension. <i>Thorax</i> , 2021, 76, 624-631.	2.7	14
93	The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?. <i>ERJ Open Research</i> , 2021, 7, 00768-2020.	1.1	14
94	Exacerbation Profile and Risk Factors in a Type-2â€œLow Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 545-553.	2.5	14
95	A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 609-615.	1.1	13
96	Increasing analytical space in gas chromatography-differential mobility spectrometry with dispersion field amplitude programming. <i>Journal of Chromatography A</i> , 2007, 1173, 129-138.	1.8	13
97	Instability of sputum molecular phenotypes in U-BIOPRED severe asthma. <i>European Respiratory Journal</i> , 2021, 57, 2001836.	3.1	13
98	Urinary metabolite of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study. <i>European Respiratory Journal</i> , 2022, 59, 2101733.	3.1	13
99	Chemometrics models for overcoming high between subject variability: applications in clinical metabolic profiling studies. <i>Metabolomics</i> , 2014, 10, 375-385.	1.4	12
100	Peripheral Interventions for Painful Stump Neuromas of the Lower Limb. <i>Clinical Journal of Pain</i> , 2018, 34, 285-295.	0.8	12
101	The role of measuring exhaled breath biomarkers in sarcoidosis: a systematic review. <i>Journal of Breath Research</i> , 2019, 13, 036015.	1.5	11
102	Investigating the safety of capsaicin cough challenge in severe asthma. <i>Clinical and Experimental Allergy</i> , 2019, 49, 932-934.	1.4	11
103	Treating asthma in the COVID-19 pandemic. <i>Thorax</i> , 2020, 75, 822-823.	2.7	11
104	Comparison of the sensitivity of patient-reported outcomes for detecting the benefit of biologics in severe asthma. <i>Chronic Respiratory Disease</i> , 2021, 18, 147997312110435.	1.0	11
105	A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes. <i>European Respiratory Journal</i> , 2022, 59, 2102603.	3.1	11
106	Clinical and transcriptomic features of persistent exacerbationâ€œprone severe asthma in Uâ€œBIOPRED cohort. <i>Clinical and Translational Medicine</i> , 2022, 12, e816.	1.7	11
107	Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarkerâ€œhigh and â€œlow severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2974-2986.	2.7	11
108	Heliox for inducible laryngeal obstruction (vocal cord dysfunction): A systematic literature review. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 255-258.	0.6	10

#	ARTICLE	IF	CITATIONS
109	Capturing and Storing Exhaled Breath for Offline Analysis. , 2019, , 13-31.		10
110	Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA). Health and Quality of Life Outcomes, 2020, 18, 336.	1.0	10
111	Fungal asthma among Ugandan adult asthmatics. Medical Mycology, 2021, 59, 923-933.	0.3	10
112	Untargeted Molecular Analysis of Exhaled Breath as a Diagnostic Test for Ventilator-Associated Lower Respiratory Tract Infections (BreathDx). Thorax, 2022, 77, 79-81.	2.7	10
113	Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort. Chest, 2021, 160, 53-64.	0.4	10
114	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. European Respiratory Journal, 2022, 59, 2100142.	3.1	10
115	Comparative In Vivo Lung Delivery of Hydrofluoroalkane-Salbutamol Formulation Via Metered-Dose Inhaler Alone, With Plastic Spacer, or With Cardboard Tube. Chest, 2001, 119, 1018-1020.	0.4	9
116	Assessing machine learning algorithms for self-management of asthma. , 2017, , .		9
117	A pilot study to investigate the use of serum inhaled corticosteroid concentration as a potential marker of treatment adherence in severe asthma. Journal of Allergy and Clinical Immunology, 2017, 139, 1037-1039.e1.	1.5	9
118	Detection and quantification of exhaled volatile organic compounds in mechanically ventilated patients – comparison of two sampling methods. Analyst, The, 2021, 146, 222-231.	1.7	8
119	Evaluation of an Aspergillus IgG/IgM lateral flow assay for serodiagnosis of fungal asthma in Uganda. PLoS ONE, 2021, 16, e0252553.	1.1	8
120	Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. European Respiratory Journal, 2022, 59, 2100768.	3.1	8
121	Reclassification of Bronchodilator Reversibility in the U-BIOPRED Adult Asthma Cohort Using zÅScores. Chest, 2018, 153, 1070-1072.	0.4	7
122	Development of a sensor device with polymer-coated piezoelectric micro-cantilevers for detection of volatile organic compounds. Measurement Science and Technology, 2020, 31, 035103.	1.4	7
123	Diagnosing Asthma with and without Aerosol-Generating Procedures. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4243-4251.e7.	2.0	7
124	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3362-3376.	2.7	7
125	Breath analysis for label-free characterisation of airways disease. European Respiratory Journal, 2018, 51, 1702586.	3.1	6
126	Two pathways, one patient; UK asthma guidelines. Thorax, 2018, 73, 797-798.	2.7	6



#	ARTICLE	IF	CITATIONS
127	UK consensus statement on the diagnosis of inducible laryngeal obstruction in light of the COVID-19 pandemic. <i>Clinical and Experimental Allergy</i> , 2020, 50, 1287-1293.	1.4	6
128	Serum Inhaled Corticosteroid Detection for Monitoring Adherence in Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4279-4287.e6.	2.0	6
129	Long-Term Effects of Allergen Sensitization and Exposure in Adult Asthma. <i>World Allergy Organization Journal</i> , 2009, 2, 83-90.	1.6	5
130	Sex and intimacy in people with severe asthma: a qualitative study. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000382.	1.2	5
131	Breath biomarkers in asthma: we're getting answers, but what are the important questions?. <i>European Respiratory Journal</i> , 2019, 54, 1901411.	3.1	4
132	Soluble interleukin-2 receptor in exhaled breath condensate in pulmonary sarcoidosis: a cross-sectional pilot study. <i>Journal of Breath Research</i> , 2021, 15, 016016.	1.5	4
133	Outcomes over the first two years of treatment with mepolizumab in severe asthma. <i>European Respiratory Journal</i> , 2021, 58, 2101313.	3.1	3
134	Breath and plasma metabolomics to assess inflammation in acute stroke. <i>Scientific Reports</i> , 2021, 11, 21949.	1.6	3
135	Differentiating Throat Symptoms in Inducible Laryngeal Obstruction From Anaphylaxis—Information for Patients and Health Care Professionals. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 645-646.	2.0	3
136	Metabolic phenotyping of acquired ampicillin resistance using microbial volatiles from <i>Escherichia coli</i> cultures. <i>Journal of Applied Microbiology</i> , 2022, 133, 2445-2456.	1.4	3
137	Fluticasone propionate bioavailability in asthma. <i>Lancet, The</i> , 2000, 356, 1681.	6.3	2
138	Montelukast for persistent asthma. <i>Lancet, The</i> , 2001, 358, 1455.	6.3	2
139	Exercise-induced bronchoconstriction: A survey of diagnostic practice in secondary care across the United Kingdom. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2130-2132.	2.7	2
140	Prevalence of <i>Aspergillus fumigatus</i> skin positivity in adults without an apparent/known atopic disease in Uganda. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110390.	1.1	2
141	Clinical biomarkers and noninvasive assessment of severe asthma. , 2019, , 93-112.		2
142	Systematic review of the effectiveness of non-pharmacological interventions used to treat adults with inducible laryngeal obstruction. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001199.	1.2	2
143	On-demand relief treatment for asthma. <i>Lancet, The</i> , 2001, 357, 1882.	6.3	1
144	Same-day repeatability of fractional exhaled nitric oxide in severe asthma. <i>European Respiratory Journal</i> , 2021, 57, 2003391.	3.1	1

#	ARTICLE	IF	CITATIONS
145	Can FeNO help guide first-line treatment in suspected asthma?. <i>Respirology</i> , 2021, 26, 632-633.	1.3	1
146	Clinical phenotyping. , 2020, , 321-334.		1
147	E-cigarette company tactics in sports advertising. <i>Lancet Respiratory Medicine</i> ,the, 2022, 10, 634-636.	5.2	1
148	Short- and medium-term effect of inhaled corticosteroids on exhaled breath biomarkers in severe asthma. <i>Journal of Breath Research</i> , 0, , .	1.5	1
149	Regular use of salbutamol in asthma. <i>Lancet</i> , The, 2000, 356, 853.	6.3	0
150	Evaluation of surrogate inflammatory markers for optimizing inhaled corticosteroid therapy in a real-life clinical setting. <i>Allergology International</i> , 2003, 52, 71-75.	1.4	0
151	An airway traffic jam: a plastic traffic cone masquerading as bronchial carcinoma. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220514.	0.2	0
152	Understanding antimicrobial prescribing in suspected ventilator-associated pneumonia: a prospective cohort study. <i>Access Microbiology</i> , 2020, 2, .	0.2	0
153	Reply to "Therapeutic drug monitoring of inhaled corticosteroids in exhaled breath for adherence assessment" <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4507-4508.	2.0	0